Tenax Therapeutics's Total Assets for the quarter that ended in Dec. 2023 was $11.69 Mil.
During the past 12 months, Tenax Therapeutics's average Total Assets Growth Rate was 47.80% per year.
During the past 3 years, the average Total Assets Growth Rate was 129.80% per year.
During the past 5 years, the average Total Assets Growth Rate was 28.30% per year.
During the past 10 years, the average Total Assets Growth Rate was -29.70% per year.
During the past 13 years, Tenax Therapeutics's highest 3-Year average Total Assets Growth Rate was 207.50%. The lowest was -80.70%. And the median was 9.90%.
The historical data trend for Tenax Therapeutics's Total Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
Tenax Therapeutics's Total Assets for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tenax Therapeutics (NAS:TENX) Total Assets Explanation
Note:
The Net Income data used here is four times the quarterly (Dec. 2023) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
Tenax Therapeutics's Asset Turnover for the quarter that ended in Dec. 2023 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
Tenax Therapeutics Total Assets Related Terms
Thank you for viewing the detailed overview of Tenax Therapeutics's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.
Tenax Therapeutics (Tenax Therapeutics) Business Description
Tenax Therapeutics Inc is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The company owns North American rights to develop and commercialize levosimendan and has released topline data regarding the Phase 2 clinical trial for the use of levosimendan in the treatment of Pulmonary Hypertension associated with Heart Failure and preserved Ejection Fraction.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
TENX has been successfully added to your 